Latest addition : 28 May.
The team’s objective is to design and synthesize antiviral drugs against viruses for which there is no treatment and to design more effective antiviral drugs than those currently used in therapy.
People Involved : Dr Karine Barral, Fatiha Benmansour Flaviviridae comprise major human pathogens that are grouped in three families: flaviviruses (Dengue virus (DENV), Yellow-fever virus, Japanese encephalitis virus) hepaciviruses (Hepatitis C virus) and pestiviruses. While vaccines are available that confer protection against some flaviviruses (eg: Yellow-fever and Japanese encephalitis), no vaccine has currently been fully validated conferring sufficient protection against the four (...)
Introduction The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is essential in the process of viral replication and therefore represents an obvious target of choice for antiviral products. The nucleoside is an essential part of current antiretroviral therapy. Unfortunately, treatments using nucleoside analogues lose their effectiveness over time, while simultaneously resistant viruses emerge. The abundance of HIV-1 strains resistant to multiple antiviral drugs (...)
People involved : Dr Karine Alvarez, Dr Karine Barral, Fatiha Benmansour PCML Platform : Dr Cécilia Eydoux, Prof JC Guillemot, Dr Nicolas Masse, Dr Barbara Selisko, Dr Laétitia Sthul-Gourmand We performed a screening of 17,000 compounds on the NS5 polymerase of dengue virus. It ran as follows: The primary screening of all compounds (concentration of 35 to 100 µM) The secondary screening of compounds selected in the first round (threshold to 78% inhibition) Confirmation of the activity (...)
People involved : Dr Karine Alvarez, Reuben Ovadia, Dr Stéphane Priet, Joelle Boretto-Soler The objective of this project is to develop new treatments more effective against chronic hepatitis C to stop the disease progression to cirrhosis and liver cancer. We want to develop novel inhibitors type “nucleotide analogues” targeting replicative complex of hepatitis C and in particular the NS5B polymerase. Separation of RNA synthesis in two steps biochemically and structurally distinct opens the (...)
Head Karine ALVAREZ (Researcher) Team Karine BARRAL (Researcher) Fatiha BENMANSOUR (Engineer) Joelle BORETTO-SOLER (Engineer) Reuben OVADIA (PhD Student) Karine ALVAREZ Karine BARRAL Fatiha BENMANSOUR Joelle BORETTO-SOLER Reuben OVADIA